表紙
市場調查報告書
商品編碼
200460

副甲狀腺功能低下症:開發中產品分析

Hypoparathyroidism (Hormonal Disorders) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 66 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

副甲狀腺功能低下症,是由於副甲狀腺的功能衰退使副甲狀腺素產生量降低而發生,伴隨血中鈣濃度降低、肌肉的痙攣和收縮(不自覺肌肉收縮)、其他症狀。雖有遺傳原因,不過也有甲狀腺或副甲狀腺的手術後發生,少有免疫系統障礙成為原因。治療為進行人工荷爾蒙,鈣劑和維他命的給藥等。

本報告提供副甲狀腺功能低下症的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

副甲狀腺功能低下症概要

治療藥的開發

  • 開發中產品:概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Ascendis Pharma A/S
  • 中外製藥
  • Eli Lilly and Company
  • Entera Bio Ltd
  • Pharis Biotec GmbH
  • Shire Plc

藥物簡介

暫停中的計劃

產品開發里程碑

  • 關注的新聞和新聞稿

附錄

圖表

目錄
Product Code: GMDHC13086IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Drugs In Development, 2021, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hypoparathyroidism - Overview
  • Hypoparathyroidism - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hypoparathyroidism - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hypoparathyroidism - Companies Involved in Therapeutics Development
  • Aerami Therapeutics Inc
  • Aeterna Zentaris Inc
  • Amolyt Pharma
  • Ascendis Pharma AS
  • BridgeBio Pharma Inc
  • Chugai Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Entera Bio Ltd
  • Extend Biosciences Inc
  • GC Pharma
  • ProLynx LLC
  • Hypoparathyroidism - Drug Profiles
  • ACP-014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Aerami-701 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AEZS-150 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZP-3601 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CLTX-305 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • encaleret - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXT-608 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-6272K - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PCO-371 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PLX-134 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem cell Therapy for Hypoparathyroidism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teriparatide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hypoparathyroidism - Dormant Projects
  • Hypoparathyroidism - Product Development Milestones
  • Featured News & Press Releases
  • Sep 10, 2021: Amolyt Pharma to host key opinion leader webinar and discuss results of phase I clinical trial of AZP-3601 on Friday, October 1st at 10:00am ET
  • Jul 06, 2021: Ascendis Pharma announces target enrollment achieved in the Phase 3 PaTHway trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism (HP) and provides a comprehensive global clinical program update
  • Jun 03, 2021: The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
  • Jun 01, 2021: BridgeBio Pharma receives FDA Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia type 1
  • May 18, 2021: Amolyt Pharma present new phase 1 data on AZP-3601 its parathyroid hormone analog for hypoparathyroidism, at upcoming scientific conferences
  • May 12, 2021: Ascendis Pharma announces expansion of global clinical reach for TransCon PTH with filing of the clinical trial notification for phase 3 clinical trial in adults with hypoparathyroidism in Japan
  • May 10, 2021: Ascendis Pharma announces preliminary 58-week results from open-label extension of phase 2 PaTH forward trial of TransCon PTH in adult hypoparathyroidism demonstrated durable benefit and a well-tolerated safety profile
  • May 06, 2021: Aeterna Zentaris announces the selection of a development candidate in the DC-PTH program for the potential treatment of primary hypoparathyroidism
  • May 06, 2021: Ascendis Pharma announces presentations for TransCon PTH at upcoming medical conferences
  • Mar 23, 2021: Ascendis Pharma presents 6-month open-label extension data from phase 2 path forward trial of TransCon PTH in adult Hypoparathyroidism at ENDO 2021
  • Mar 22, 2021: Amolyt Pharma presents first clinical data for AZP-3601, its parathyroid hormone analog for hypoparathyroidism, at the Endocrine Society's Virtual Annual Meeting (ENDO 2021)
  • Mar 20, 2021: BridgeBio Pharma announces proof-of-concept data of Encaleret in ADH1 at the Endocrine Society's 2021 Annual Meeting
  • Mar 16, 2021: Amolyt pharma to present preliminary phase 1 data on AZP-3601 at ENDO 2021
  • Feb 25, 2021: Entera Bio announces publication of phase 2 hypoparathyroidism study in the Journal of Bone and Mineral Research
  • Jan 06, 2021: Amolyt Pharma receives Orphan Drug Designation for AZP-3601 for the potential treatment of hypoparathyroidism
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Hypoparathyroidism, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Hypoparathyroidism - Pipeline by Aerami Therapeutics Inc, 2021
  • Hypoparathyroidism - Pipeline by Aeterna Zentaris Inc, 2021
  • Hypoparathyroidism - Pipeline by Amolyt Pharma, 2021
  • Hypoparathyroidism - Pipeline by Ascendis Pharma AS, 2021
  • Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, 2021
  • Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, 2021
  • Hypoparathyroidism - Pipeline by Eli Lilly and Co, 2021
  • Hypoparathyroidism - Pipeline by Entera Bio Ltd, 2021
  • Hypoparathyroidism - Pipeline by Extend Biosciences Inc, 2021
  • Hypoparathyroidism - Pipeline by GC Pharma, 2021
  • Hypoparathyroidism - Pipeline by ProLynx LLC, 2021
  • Hypoparathyroidism - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Hypoparathyroidism, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021